Monthly Archives: February 2020

Hospital readmissions are frequent and expensive. Thirty-day readmission rates for adult patients undergoing colectomy are as high as 25%, with inflammatory bowel disease (IBD) being a major risk factor for readmission. We sought to 1) determine the 30… Continue reading →

Mirikizumab (miri; LY3074828) is a humanized monoclonal antibody directed against the p19 subunit of IL-23, which demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial (NCT02589665) in patients with ulcerative colitis (UC)… Continue reading →

Therapeutic options for pediatric inflammatory bowel disease (PIBD) have dramatically changed over the last decades with the widespread use of biologic medications. However, the overall impact of biologic therapy on PIBD outcomes (specifically hospital… Continue reading →

Mirikizumab (LY3074828) is a humanized monoclonal antibody directed against the p19 subunit of IL-23, and had demonstrated efficacy in psoriasis, ulcerative colitis (UC), and Crohn’s disease. The effect of miri on health-related quality of life (HRQoL)… Continue reading →

Subcutaneous (SC) delivery of biologic therapies is typically self-administered via a prefilled syringe or an auto-injector. Auto-injector devices are designed to offer a more convenient and more consistent administration of the drug product. The Subcu… Continue reading →

GB004 is a small molecule prolyl hydroxylase inhibitor (PHDi) that stabilizes hypoxia inducible factors (HIF1-α), key transcription factors involved in the protective cellular responses at the intersection of hypoxia and inflammation. GB004 was selecte… Continue reading →

Toll-like receptor 4 (TLR4), the receptor for gram negative lipopolysaccharide, is upregulated in biopsies of ulcerative colitis and colorectal cancer (CRC) patients, particularly in intestinal epithelial cells (IECs). We have demonstrated that activat… Continue reading →

Vedolizumab (VDZ), a gut-selective antibody that binds specifically to integrin α4β7, is approved for treatment of adults with moderate-to-severe ulcerative colitis (UC). An association between VDZ levels and clinical remission during induction therapy… Continue reading →

An in vitro model of intestine epithelium with an immune compartment was bioengineered to mimic immunologic responses seen in inflammatory bowel disease [1]. While aspects of intestinal immunity can be modeled in transwells and 2D culture systems, 3D t… Continue reading →

Inflammatory bowel disease is a collection of disorders of the gastrointestinal tract, characterised by relapsing and remitting inflammation. Studies have reported several pharmacological or non-pharmacological interventions being effective in the mana… Continue reading →